People · Operator
Named in public records as an officer, director or promoter · active 2021–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elucida Oncology, Inc. | — | Biotechnology | Series B | $117.1M | $255.6M | 2022 |
| iBio, Inc. | — | Biotechnology | Series B | $74.4M | $96.5M | 2023 |
| Gennao Bio, Inc. | — | Biotechnology | Series B | $47.5M | $211.8M | 2021 |
Gary Sender at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gary Sender on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Smith | 1 | 20 |
| Peter Thompson | 1 | 16 |
| Isaac Blech | 1 | 14 |
| William Clark | 1 | 12 |
| Chau Khuong | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| Robert Ruffolo | 1 | 8 |
| James Hill | 1 | 6 |
| Craig Gordon | 1 | 6 |
| Michael T. Smith | 1 | 5 |
| Bradley Campbell | 1 | 5 |
| Robert Erwin | 1 | 4 |
| ROBERT KAY | 1 | 4 |
| Tim Boris | 1 | 3 |
| Robert Essner | 1 | 3 |
| Isaac A. Blech | 1 | 3 |
| Bruce Turner | 1 | 2 |
| David A Arkowitz | 1 | 2 |
| Evert Schimmelpennink | 1 | 2 |
| Gary A. Sender | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.